Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
From Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
From Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
From Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
04/29/2024
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
From Neurology

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Expert Insights Quiz
LAIs and Telehealth Psychiatric Care
10/24/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
10/24/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Adult ADHD Diagnosis Rates
10/23/2024
Take the quiz to test your knowledge!
Take the quiz to test your knowledge!
Take the quiz to test your...
10/23/2024
Psych Congress Network
Jonathan Meyer
Quiz
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments?
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine...
10/23/2024
Psych Congress NP Institute
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Telehealth Versus In-Person Psychiatric Care
09/19/2024
Do you know what the data from randomized control trials say?
Do you know what the data from randomized control trials say?
Do you know what the data from...
09/19/2024
Psych Congress Network
How many ADHD prescriptions are affected by the med shortage?
Quiz
How many ADHD prescriptions are affected by the med shortage?
09/17/2024
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent...
09/17/2024
Psych Congress Network
Symptom Reduction in Bipolar Disorder Treatment
Expert Insights Quiz
Symptom Reduction in Bipolar Disorder Treatment
09/13/2024
Test your knowledge
Test your knowledge
Test your knowledge
09/13/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
CDC/AAP Treatment Guidelines for Pediatric ADHD
09/11/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
09/11/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network

Insights

marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Improving Cognition in Patients With Alzheimer’s Disease
Videos
Improving Cognition in Patients With Alzheimer’s Disease
11/11/2020
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric...
11/11/2020
Psych Congress Network
Jonathan Meyer, MD
Videos
Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments
11/11/2024
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his...
11/11/2024
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Desiree Matthews
Schizophrenia Conference Insights
New Class of Medication Offers Innovative Treatment for Schizophrenia Symptoms
11/07/2024
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights...
11/07/2024
Psych Congress Network
Marc Agronin
Videos
Implementing Alzheimer Disease Prevention Practices
11/02/2024
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some...
11/02/2024
Psych Congress Network
Michelle Martel, PhD
Q&As
When It Comes to ADHD in Women, There's Still So Much to Learn
10/31/2024
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares...
10/31/2024
Psych Congress Network
Andrew Penn
Q&As
Psychedelics: New Research, Regulations, and Horizons
10/30/2024
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must...
10/30/2024
Psych Congress Network
Jo Hughes
Q&As
Unpacking the Pressing Challenges of Polypharmacy in Psychiatry
10/30/2024
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY,...
10/30/2024
Psych Congress Network
Beau Kilmer, PhD
Q&As
Psychedelic Policy and Market Considerations
10/28/2024
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the...
10/28/2024
Psych Congress Network
Christoph Correll, MD.
Videos
Strategies to Manage Adverse Effects From Schizophrenia Treatment
10/28/2024
Christoph Correll, MD, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder
Christoph Correll, MD, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder
Christoph Correll, MD, offers...
10/28/2024
Psych Congress Network
Christoph Correll, MD
Videos
Beyond D2 Receptor Manipulation: Novel Agents for Schizophrenia Treatment
10/16/2024
Christoph Correll, MD, provides a thorough pharmacological overview of the traditional and novel treatments available for schizophrenia.
Christoph Correll, MD, provides a thorough pharmacological overview of the traditional and novel treatments available for schizophrenia.
Christoph Correll, MD, provides...
10/16/2024
Psych Congress Network

Practice Tools

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
Conference Coverage
Flexible Dosing of Esketamine Nasal Spray Effective Over Long-Term
11/12/2024
Analysis of a long-term extension study of flexibly dosed esketamine nasal spray, in combination with an oral antidepressant, found durable long-term efficacy and safety of the treatment whether dosed weekly, every other week, or every 4...
Analysis of a long-term extension study of flexibly dosed esketamine nasal spray, in combination with an oral antidepressant, found durable long-term efficacy and safety of the treatment whether dosed weekly, every other week, or every 4...
Analysis of a long-term...
11/12/2024
Psychiatry & Behavioral Health
Jonathan Meyer, MD
Videos
Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments
11/11/2024
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his...
11/11/2024
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Stephen M. Stahl
Conference Coverage
At the NEI Fall Congress, Leading Faculty Reflect on the Evolution of Psychiatry and What the Future May Hold
11/08/2024
The 2024 Neuroscience Education Institute (NEI) Fall Congress commenced with opening remarks from Andrew J. Cutler, MD, Chairman, and the highly anticipated keynote address from Stephen M. Stahl, MD, PhD, DSc (Hon.), Chairman Emeritus.
The 2024 Neuroscience Education Institute (NEI) Fall Congress commenced with opening remarks from Andrew J. Cutler, MD, Chairman, and the highly anticipated keynote address from Stephen M. Stahl, MD, PhD, DSc (Hon.), Chairman Emeritus.
The 2024 Neuroscience Education...
11/08/2024
Psychiatry & Behavioral Health
Desiree Matthews
Schizophrenia Conference Insights
New Class of Medication Offers Innovative Treatment for Schizophrenia Symptoms
11/07/2024
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights...
11/07/2024
Psych Congress Network
NEI Fall Congress 2024
Conference Coverage
Medication Management, Care Enhancements Under the Spotlight at the 20th Annual NEI Fall Congress
11/07/2024
The 20th annual NEI Fall Congress provides a space—both in person and online—where leading minds in psychiatry share current and emerging treatment strategies with the next generation of mental health care professionals.
The 20th annual NEI Fall Congress provides a space—both in person and online—where leading minds in psychiatry share current and emerging treatment strategies with the next generation of mental health care professionals.
The 20th annual NEI Fall...
11/07/2024
Psychiatry & Behavioral Health
Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network

News Articles

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
04/29/2024
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
Illustration of the brain
News
Antipsychotics for Dementia Associated With More Adverse Outcomes Than Previously Thought
04/22/2024
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients...
04/22/2024
Psych Congress Network
Doctors examine brain scans
News
Rate of Frontotemporal Dementia in Patients With ALS Higher Than Previous Estimates
03/04/2024
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
A person steps onto a scale
News
Neuropsychiatric Side Effects Reported With CB1 Weight-Loss Drug
10/16/2024
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with...
10/16/2024
Psych Congress Network
Increase in Suicidality Associated With FDA Black Box Warning Implementation
News
Increase in Suicidality Associated With FDA Black Box Warning Implementation
10/11/2024
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on...
10/11/2024
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
News
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
10/09/2024
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may...
10/09/2024
Psych Congress Network

Posters

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Withdrawal Catatonia: A Rare Case of Treatment-Resistant Catatonia Secondary to Quetiapine Withdrawal
Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...
10/26/2023
Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study
In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
10/26/2023
Utilization of Psychiatric Pharmacogenomic Testing by Primary Care Physicians and Advanced Practice Providers: Confidence and Implementation Barriers
Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...
10/26/2023
Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials
Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...
10/26/2023
Veterans’ Intensive​ PCMHI Boot Camp​ (VIP Boot Camp)
Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system
10/26/2023
Understanding the Real-World Prescription Patterns and Impact of Atypical Antipsychotic Augmentation Timing on Healthcare Cost in Adult Major Depressive Disorder in the United States: A Systematic Literature Review
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
10/26/2023
Unique Features of the Rapid Mood Screener Enable Detection of Bipolar I Disorder in a Primary Care Practice
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
10/26/2023
Use Of VMAT2 Inhibitors For Tardive Dyskinesia In Geriatric Populations - A Case Study
This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...
10/26/2023
Using Chess as a Novel Means to Cure Treatment Refractory Catatonia
The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...
10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use